博舒替尼
医学
耐受性
交叉研究
生物利用度
药代动力学
不利影响
药理学
胃肠病学
内科学
病理
安慰剂
酪氨酸激酶
受体
替代医学
尼罗替尼
作者
Poe‐Hirr Hsyu,Daniela Soriano Pignataro,Kyle T. Matschke
摘要
This study evaluated the absolute bioavailability of bosutinib and assessed its safety and tolerability after single‐dose oral and intravenous administration. In this phase 1 open‐label, 2‐sequence, 2‐period crossover study, healthy, fed subjects aged 18−55 years were randomized to 1 of 2 treatment sequences (n = 7/sequence): oral bosutinib (100 mg × 5) followed by intravenous bosutinib (120 mg in approximately 240 mL over 1 hour), with a ≥14‐day washout, or intravenous bosutinib and then oral bosutinib. Results of plasma pharmacokinetics analyses demonstrated that exposure to intravenous bosutinib was 3‐fold higher than for oral bosutinib (16.2 and 5.5 ng·h/mL/mg, respectively), and mean terminal half‐life was similar (35.5 and 31.7 hours). The ratio of adjusted geometric means (90%CI) for the dose‐normalized area under the plasma concentration–time profile (AUC0−∞/D) was 33.85% (30.65%‒37.38%). Most treatment‐emergent adverse events (AEs) were mild in severity. Gastrointestinal (GI) AEs occurred in 9 of 13 subjects given oral bosutinib, whereas no subjects given intravenous bosutinib experienced GI AEs, suggesting bosutinib present in the GI tract had an effect. Bosutinib exhibited an absolute bioavailability of 33.85% based on the ratio of AUC0−∞/D. Both oral and intravenous bosutinib were safe and well tolerated in healthy, fed adult subjects.
科研通智能强力驱动
Strongly Powered by AbleSci AI